SLCO1B1 Antibody, FITC conjugated

說明書

中文名稱：

SLCO1B1兔多克隆抗體, FITC偶聯
貨號：

CSB-PA896932LC01HU
規格：

￥880
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) SLCO1B1 Polyclonal antibody
Uniprot No.：

Q9Y6L6
基因名：

SLCO1B1
別名：

Liver-specific organic anion transporter 1 antibody; LST-1 antibody; LST1 antibody; OATP-2 antibody; OATP-C antibody; OATP1B1 antibody; OATPC antibody; SLC21A6 antibody; SLCO1B1 antibody; SO1B1_HUMAN antibody; Sodium-independent organic anion-transporting polypeptide 2 antibody; Solute carrier family 21 member 6 antibody; Solute carrier organic anion transporter family member 1B1 antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human Solute carrier organic anion transporter family member 1B1 protein (426-537AA)
免疫原種屬：

Homo sapiens (Human)
標記方式：

FITC
克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
產品提供形式：

Liquid
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
基因功能參考文獻：
1. SLCO1B1 c.388A>G, c.521T>C and g.89595T>C polymorphisms may not be useful as genetic markers of lipid-lowering response to simvastatin therapy. PMID: 29575099
2. Neither the ABCB1 C3435T nor the SLCO1B1 T521C polymorphism affected edoxaban PK. PMID: 27897269
3. Subjects with SLCO1B1 c.388AG and c.388GG genotypes (i.e., increased OATP1B1 transport activity for certain substrates) had lower concentrations of CPI than those with SLCO1B1 c.388AA. PMID: 29777022
4. Advanced pancreatic cancer patients with advanced pancreatic cancer with the solute carrier organic anion transporter family member 1B1 (SLCO1B1) rs4149086 AG or GG genotype may obtain good clinical results when treated with S-1-containing regimens. PMID: 29683977
5. Study determined that SLCO1B1 rs4149056 T/C genotype and C allele may be associated with exudative age-related macular degeneration, as well as with elevated serum SLCO1B1 levels. Also, higher serum SLCO1B1 levels were found to be associated with early and exudative age-related macular degeneration. PMID: 30010042
6. OATP1B1 genetic polymorphism is associated with decreased uptake of tamoxifen and its metabolite, endoxifen. PMID: 28627631
7. SLCO1A2 and SLCO1B1 gene treatment over time interactions were associated with gametocytemia clearance rate. PMID: 28975866
8. SLCO1B1 rs4149056 genetic variants can affect the HD-MTX-related toxicity in Chinese patients with NHL. PMID: 29095107
9. This nested case-control study showed that rs4149056 (SLCO1B1, 521T > C) was associated with rosuvastatin-induced myotoxicity in Chinese patients, and that 521C mutant allele increased the risk of rosuvastatin-associated myotoxicity. PMID: 28812116
10. There is lower prevalence of statin-induced myopathy-linked C allele of rs4149056 in SLCO1B1 gene in Emirati population, compared to Caucasians and Africans. PMID: 29534995
11. sorafenib-beta-D-glucuronide transport by OATP1B1 or murine Oatp1b2 was effectively inhibited by rifampin. PMID: 28371445
12. SLCO1B1 and ABCG2 polymorphisms are better predictors of rosuvastatin exposure than ethnicity alone and could be considered in precision medicine dosing of rosuvastatin. PMID: 28385543
13. results suggested that Gly71Arg and Asn130Asp mutations in UGT1A1 and OATP2 genes might be involved in the development of hyperbilirubinemia in neonates. PMID: 26960716
14. This review describes what is currently known regarding SLCO1B1 genotype, OATP1B1 protein expression and interindividual and interethnic consequences to drug disposition, with particular focus on statin pharmacokinetics and implications for drug response and toxicity--{REVIEW} PMID: 27936281
15. Data suggest that OATP1B1, OATP1B3, and OATP2B1 participate in transport of perfluoroalkyl acids in hepatocytes; environmental pollutants transported include PFBS (perfluorobutane sulfonate), PFHxS (perfluorohexane sulfonate), and PFOS (perfluorooctane sulfonate). PMID: 28013215
16. Associations between SLCO1B1 521C and cholesterol response were not detected in African Americans (n = 333). Associations between CYP3A4*22 or CYP3A5*3 and cholesterol response were not detected in whites or African Americans. PMID: 28482130
17. Although we have found quite a large number of genetic variants of the UGT1A1 and SLCO1B1 genes in the African-American population, it does not appear that they have a significant impact on the incidence of hyperbilirubinemia among this group of infants. PMID: 27977017
18. We compared the carrier frequency of Cytochrome P450 Enzymes and Transport Proteins markers among the Russian population living in Moscow with Dagestan ethnic groups. Statistically significant differences for the following gene polymorphisms: CYP2C19*17, CYP2C9*3, ABCB1 (C3435T), SLCO1B1*5 were found between the Russian population and the three ethnic groups of the Dagestan republic. PMID: 29023140
19. plasma rifampicin concentrations did not differ significantly between the various genotypes of the rs4149032 polymorphism of the SLCO1B1 gene in a South Indian population PMID: 27510251
20. OATP1B1 showed high interindividual variability in relative protein expression but no statistically significant difference among the studied age groups. PMID: 27098745
21. Organic anion-transporting polypeptides exert strong impact on disposition and toxicity of antitumor drugs. (Review) PMID: 27449599
22. SLCO1B1*5 allele variants and patient age predict the likelihood of young women with breast cancer developing chemotherapy-induced amenorrhea. PMID: 27234217
23. SLCO1B1 polymorphisms appear to be associated with the development of adverse drug reactions to regorafenib. PMID: 28157071
24. Polymorphisms in SLCO1B1 and UGT1A1 are associated with several different sorafenib side effects PMID: 27533851
25. OATP1A2, OATP1B1, and OATP2B1 can mediate cellular uptake of ochratoxin A, which could aggravate OTA toxicity. PMID: 28532671
26. Our results did not indicate a strong association between OATP1B1 or OATP1B3 inhibition and hyperbilirubinemia PMID: 28063966
27. Polymorphisms of the SLCO1B1 gene ate used for predicting risk of adverse events when using statins. PMID: 28252633
28. Critical amino acid residues in the predicted transmembrane pore influencing transport kinetics of the hepatic drug transporter OATP1B1 have been identified. PMID: 27594653
29. Genetic polymorphisms of the UGT1A1 promoter, specifically the T-3279G phenobarbital-responsive enhancer module and (TA)7 dinucleotide repeat, as well as the intron and coding region variants of the OATP2, HMOX1, and BLVRA genes, were significantly higher among the cases than the controls. PMID: 27943244
30. SLCO1B1 genotype was not associated with the risk of statin-associated muscle symptoms. PMID: 27595674
31. these findings demonstrate an important role for OATP1B1 in the systemic pharmacokinetics of multiple drugs used in the treatment of acute myeloid leukemia PMID: 26663398
32. Genetic link with cholelithiasis among pediatric SCA Tunisian patients: Examples of UGT1A1, SLCO1A2 and SLCO1B1. PMID: 26146896
33. SLCO1B1 rs113681054, SLCO1B1*5 (rs4149056), CYP3A4*1G (rs2242480), and CYP3A4*5 (rs776746) polymorphisms had no effect on the PK/PD of ticagrelor in healthy Chinese volunteers PMID: 28049954
34. SLCO1B1 gene variants could affect the pharmacodynamics of rocuronium. PMID: 25279974
35. Polymorphism of SLCO1B1 c.521 T > C could be a strong predictor of 6-MP dose reduction in maintenance chemotherapy in childhood ALL. PMID: 25939871
36. No significant difference was observed in the lipid-lowering efficacy of statins between the wild and variant genotypes of SLCO1B1. PMID: 25932441
37. Patients under pravastatin treatment prior to inguinal hernia repair presented with lower postoperative IL-10 levels with respect to the baseline concentration, regardless of the presence or absence of SLCO1B1 *1 or SLCO1B1 *5 polymorphisms. PMID: 26826613
38. transport of CPR I mediated by OATP1B1 and OATP1B3 and the transport of CPR III mediated by OATPs 1B1, 1B3 and 2B1 is time-dependent, can be saturated and inhibited PMID: 26383540
39. The SLCO1B1 rs1104581 polymorphism, weight, and gender appear to play important roles for rifabutin efficiency in African HIV-Infected patients with tuberculosis. PMID: 26482301
40. Results identified interethnic differences of genetic variations of the SLCO1B1, SLCO1B3, and SLCO2B1 genes in Korean population compared with other ethnic groups. PMID: 26409184
41. SLCO1B1 variants are strongly associated with an increased risk of enalapril-induced cough. PMID: 26607661
42. TM11 of OATP1B1 may face the substrate interaction pocket. PMID: 26562723
43. OATP1B1- and OATP1B3-humanized mice can be used as in vivo tools to assess and possibly predict clinically relevant DDIs. PMID: 26474710
44. The HEK-293 cell lines stably expressing human OATP1B1-wild and variant (HEK-OATP1B1, *1b and *15) are potential models to study drug transport in vitro PMID: 27455553
45. Patients with better muscle function had the highest concentration of CK, IL-1, and TNF-a compared with less muscle function PMID: 26380303
46. the polymorphism rs2306283 at the SLCO1B1 gene determines greater HDL-C concentrations in response to atorvastatin medication in Chilean hypercholesterolemic subjects. PMID: 26334272
47. Results show ticagrelor pharmacokinetics to be influenced by SNPs in SLCO1B1 though no detectable effects on efficacy or safety were found PMID: 25935875
48. Down-regulation of OATP1B1/3 proteins may contribute to pathogenesis of jaundice accompanying advanced cholestatic liver diseases. PMID: 26191226
49. SLCO1B1 and SLCO1B3 polymorphisms contributed to an increased risk of neonatal hyperbilirubinemia. PMID: 26146841
50. Misoprostol acid was transported across a blood-brain barrier model by MRP4 and SLCO1B1 PMID: 26122863
顯示更多

收起更多
相關疾病：

Hyperbilirubinemia, Rotor type (HBLRR)
亞細胞定位：

Basolateral cell membrane; Multi-pass membrane protein. Note=Detected in basolateral membranes of hepatocytes.
蛋白家族：

Organo anion transporter (TC 2.A.60) family
組織特異性：

Highly expressed in liver, at the basolateral membranes of centrilobular hepatocytes. Not detected in heart, brain, placenta, lung, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, ovary, small intestine, colon and leukocyte.
數據庫鏈接：

HGNC: 10959

OMIM: 237450

KEGG: hsa:10599

STRING: 9606.ENSP00000256958

UniGene: Hs.449738

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human